Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.77 USD
+0.04 (1.07%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:24 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Arbutus Biopharma Corporation [ABUS]
Reports for Purchase
Showing records 1 - 20 ( 194 total )
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
2Q Recap: Data at AASLD in November Could Highlight Imdusiran''s Potential As Part of a HBV Finite Cure; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
IM-PROVE II Study Preliminary Dataset Shows Clear Efficacy Signal With Immunotherapeutic Combination
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Imdusiran Shows Durable HBsAg Reductions After EoT, With Two Patients Reaching 12 Weeks Off-Treatment
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
1Q24 Recap: EASL Presentations to Feature End-of-Treatment Data From Two Imdusiran Phase 2a Studies; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
4Q Recap; Expecting Three Data Readouts Around EASL 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Three Data Readouts to Showcase Imdusiran in Different Combinations Against HBV; Cash Runway Out to 1Q26; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
3Q Recap; AASLD Late-Breaking Presentation to Provide First Look at Imdusiran Triple Combination Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Pipeline Updates Extend Cash Runway Out to 3Q25; Imdusiran Triple Combination Study Data on Target in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
2Q Recap: New Combo Data to Inform Imdusiran''s Role in HBV Finite Therapy; NZ Medsafe Approved AB-101 CTA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
New C-Suite Appointments Bring Additional Talent to Key Positions; Expecting Multiple Milestones in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Early AB-729/IFN Combination Data Are Encouraging; AB-729/ Immunotherapeutic Combination Data in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
1Q Recap: Phase 2a AB-729 Combo Data in 2Q23 Among Three Clinical Data Readouts This Year; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
AB-729 Continues to Show Evidence As a Potential Cornerstone Treatment in HBV Functional Cure; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
AB-101 Phase 1 Study''s Initiation Delayed Due to IND Hold; Our Thesis Remains Focused on AB-729; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Arbutus and Genevant File Patent Infringement Against Pfizer/BioNTech on Unlicensed Use of LNP Tech; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Dosing Begins in SAD Study of RNA Destabilizer AB-161, A Potential Component of an All-Oral HBV Treatment; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
ICAR 2023: Two Presentations in Our Coverage Universe Provide Early Datasets in COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
4Q Recap; Three Data Readouts in 2023 Could Inform AB-729''s Role in Finite HBV Therapy; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Preliminary Data Confirm Consistent HBsAg Lowering Effect in Fully Enrolled AB-729, Peg-IFN Combo Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E